Literature DB >> 25962985

Serine enantiomers as diagnostic biomarkers for schizophrenia and bipolar disorder.

Kenji Hashimoto1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25962985     DOI： 10.1007/s00406-015-0602-4

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN： 0940-1334            Impact factor:   5.270


× No keyword cloud information.
  17 in total

1.  Blood D-serine levels as a predictive biomarker for the rapid antidepressant effects of the NMDA receptor antagonist ketamine.

Authors:  Kenji Hashimoto
Journal:  Psychopharmacology (Berl)       Date:  2014-09-05       Impact factor: 4.530

2.  A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia.

Authors:  Inna Bendikov; Carmit Nadri; Shirly Amar; Rogerio Panizzutti; Joari De Miranda; Herman Wolosker; Galila Agam
Journal:  Schizophr Res       Date:  2006-12-06       Impact factor: 4.939

3.  Increased levels of glutamate in brains from patients with mood disorders.

Authors:  Kenji Hashimoto; Akira Sawa; Masaomi Iyo
Journal:  Biol Psychiatry       Date:  2007-06-15       Impact factor: 13.382

4.  Markers of glutamate signaling in cerebrospinal fluid and serum from patients with bipolar disorder and healthy controls.

Authors:  Erik Pålsson; Joel Jakobsson; Kristoffer Södersten; Yuko Fujita; Carl Sellgren; Carl-Johan Ekman; Hans Ågren; Kenji Hashimoto; Mikael Landén
Journal:  Eur Neuropsychopharmacol       Date:  2014-11-13       Impact factor: 4.600

5.  Increased D-amino acid oxidase expression in the bilateral hippocampal CA4 of schizophrenic patients: a post-mortem study.

Authors:  Gregor Habl; Mathias Zink; Georg Petroianu; Manfred Bauer; Thomas Schneider-Axmann; Martina von Wilmsdorff; Peter Falkai; Fritz A Henn; Andrea Schmitt
Journal:  J Neural Transm (Vienna)       Date:  2009-10-13       Impact factor: 3.575

6.  D-serine plasma concentration is a potential biomarker of (R,S)-ketamine antidepressant response in subjects with treatment-resistant depression.

Authors:  Ruin Moaddel; David A Luckenbaugh; Ying Xie; Alma Villaseñor; Nancy E Brutsche; Rodrigo Machado-Vieira; Anuradha Ramamoorthy; Maria Paz Lorenzo; Antonia Garcia; Michel Bernier; Marc C Torjman; Coral Barbas; Carlos A Zarate; Irving W Wainer
Journal:  Psychopharmacology (Berl)       Date:  2014-07-24       Impact factor: 4.530

7.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.

Authors:  J H Krystal; L P Karper; J P Seibyl; G K Freeman; R Delaney; J D Bremner; G R Heninger; M B Bowers; D S Charney
Journal:  Arch Gen Psychiatry       Date:  1994-03

8.  Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia.

Authors:  Kenji Hashimoto; Takeshi Fukushima; Eiji Shimizu; Naoya Komatsu; Hiroyuki Watanabe; Naoyuki Shinoda; Michiko Nakazato; Chikara Kumakiri; Shin-ichi Okada; Hisanori Hasegawa; Kazuhiro Imai; Masaomi Iyo
Journal:  Arch Gen Psychiatry       Date:  2003-06

9.  Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients.

Authors:  Takeshi Fukushima; Hideaki Iizuka; Ayaka Yokota; Takehiro Suzuki; Chihiro Ohno; Yumiko Kono; Minami Nishikiori; Ayaka Seki; Hideaki Ichiba; Yoshinori Watanabe; Seiji Hongo; Mamoru Utsunomiya; Masaki Nakatani; Kiyomi Sadamoto; Takashi Yoshio
Journal:  PLoS One       Date:  2014-07-08       Impact factor: 3.240

10.  Biological insights from 108 schizophrenia-associated genetic loci.

Authors: 
Journal:  Nature       Date:  2014-07-22       Impact factor: 49.962
View more
  7 in total

1.  Regulation of glutamate transporter 1 via BDNF-TrkB signaling plays a role in the anti-apoptotic and antidepressant effects of ketamine in chronic unpredictable stress model of depression.

Authors:  Wen-Xue Liu; Jing Wang; Ze-Min Xie; Ning Xu; Guang-Fen Zhang; Min Jia; Zhi-Qiang Zhou; Kenji Hashimoto; Jian-Jun Yang
Journal:  Psychopharmacology (Berl)       Date:  2015-10-29       Impact factor: 4.530

2.  Morphological and functional alterations in patients with schizophrenia spectrum disorders.

Authors:  Andrea Schmitt; Peter Falkai
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-02       Impact factor: 5.270

3.  Metabolomic and proteomic profiling in bipolar disorder patients revealed potential molecular signatures related to hemostasis.

Authors:  Henrique Caracho Ribeiro; Partho Sen; Alex Dickens; Elisa Castañeda Santa Cruz; Matej Orešič; Alessandra Sussulini
Journal:  Metabolomics       Date:  2022-08-03       Impact factor: 4.747

4.  Targeting D-Amino Acid Oxidase (DAAO) for the Treatment of Schizophrenia: Rationale and Current Status of Research.

Authors:  Chien-Yi Kuo; Chieh-Hsin Lin; Hsien-Yuan Lane
Journal:  CNS Drugs       Date:  2022-10-04       Impact factor: 6.497

Review 5.  Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational Biomarker.

Authors:  Kenji Hashimoto
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

6.  Effect of DAOA genetic variation on white matter alteration in corpus callosum in patients with first-episode schizophrenia.

Authors:  Wenjun Su; Tianyuan Zhu; Lihua Xu; Yanyan Wei; Botao Zeng; Tianhong Zhang; Huiru Cui; Junjie Wang; Yuping Jia; Jinhong Wang; Donald C Goff; Yingying Tang; Jijun Wang
Journal:  Brain Imaging Behav       Date:  2021-08       Impact factor: 3.978

7.  Blood metabolomics analysis identifies abnormalities in the citric acid cycle, urea cycle, and amino acid metabolism in bipolar disorder.

Authors:  Noriko Yoshimi; Takashi Futamura; Keiji Kakumoto; Alireza M Salehi; Carl M Sellgren; Jessica Holmén-Larsson; Joel Jakobsson; Erik Pålsson; Mikael Landén; Kenji Hashimoto
Journal:  BBA Clin       Date:  2016-04-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.